Clinical trial
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With…
NCT00292045 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00292045 |
|---|---|
| Title | Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer |
| Official title | Phase 1 Study of Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With High-risk Stage D1 or Advanced Prostate Cancer |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | NY-ESO-1 protein/CpG 7909 |
| Enrollment | 15 |
| Start date | Oct 27, 2004 |
| Primary completion | Jan 9, 2006 |
| Completion | Jan 9, 2006 |
| First posted | Feb 15, 2006 |
| Last update posted | Oct 4, 2023 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: